Lunenfeld B, Blankstein J, Kotev-Emeth S, Kokia E, Geier A
Hum Reprod. 1986 Nov;1(7):435-9. doi: 10.1093/oxfordjournals.humrep.a136449.
Data on the safety of agents used to induce ovulation in women are presented, with a special reference to the normality of children at birth and puberty. No overall increase in anomalies has been found after the use of clomiphene citrate. This drug has been given up to day 35 of pregnancy, and its safety in these circumstances requires further analysis. More studies will also be needed on offspring as they pass through puberty, to ensure there are no defects in their Müllerian system. No increase in anomalies has been noted after the use of human menopausal gonadotrophins (HMG). The onset of menstrual rhythms and other parameters in the offspring appear to be normal. No increase in various cancers has been identified following the use of clomiphene or HMG, although most treated women have yet to enter the high risk years.
本文介绍了用于诱导女性排卵药物的安全性数据，特别提及了出生时及青春期儿童的正常情况。使用枸橼酸氯米芬后未发现异常情况总体增加。该药物已在妊娠第35天前使用，其在这些情况下的安全性需要进一步分析。随着子代进入青春期，还需要更多研究以确保其苗勒氏系统无缺陷。使用人绝经期促性腺激素（HMG）后未发现异常情况增加。子代月经周期的开始及其他参数似乎正常。使用氯米芬或HMG后未发现各类癌症增加，尽管大多数接受治疗的女性尚未进入高危年龄段。
